Centre de Recherche Des Cordeliers, Equipe Labellisée Par la Ligue Contre le Cancer, Université de Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France.
Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France.
Oncoimmunology. 2023 Feb 17;12(1):2180237. doi: 10.1080/2162402X.2023.2180237. eCollection 2023.
Accumulating evidence indicates that Toll-like receptor (TLR) agonists proficiently (re)instore cancer immunosurveillance as immunological adjuvants. So far, three TLR agonists have been approved by regulatory agencies for use in oncological applications. Additionally, these immunotherapeutics have been extensively investigated over the past few years. Multiple clinical trials are currently evaluating the combination of TLR agonists with chemotherapy, radiotherapy, or different immunotherapies. Moreover, antibodies targeting tumor-enriched surface proteins that have been conjugated to TLR agonists are being developed to stimulate anticancer immune responses specifically within the tumor microenvironment. Solid preclinical and translational results support the favorable immune-activating effects of TLR agonists. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for anticancer immunotherapy.
越来越多的证据表明，Toll 样受体 (TLR) 激动剂作为免疫佐剂，能够有效地恢复癌症免疫监视。迄今为止，已有三种 TLR 激动剂被监管机构批准用于肿瘤学应用。此外，这些免疫疗法在过去几年中得到了广泛的研究。目前，多项临床试验正在评估 TLR 激动剂与化疗、放疗或不同免疫疗法的联合应用。此外，正在开发针对富含肿瘤表面蛋白的抗体与 TLR 激动剂的偶联物，以在肿瘤微环境中特异性地刺激抗肿瘤免疫反应。坚实的临床前和转化研究结果支持 TLR 激动剂具有良好的免疫激活作用。在这里，我们总结了 TLR 激动剂在癌症免疫治疗方面的最新临床前和临床进展。
